Try Ask OE! Our NEW Advanced AI Enabled Search
Dive into the Largest Database of
Musculoskeletal Evidence
ACE Reports.
Spine
Durable chronic low back pain reductions up to 24 months after treatment for an accessible, 8-week, in-home behavioral skills-based virtual reality program: a randomized controlled trial.
Pain Med. 2023 01-Oct;():. 10.1093/pm/pnad070
Durable chronic low back pain reductions up to 24 months after treatment for an accessible, 8-week, in-home behavioral skills-based virtual reality program: a randomized controlled trial.
Pain Med. 2023 01-Oct;():. 10.1093/pm/pnad070
Trauma
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
J Bone Joint Surg Am. 2020 ;():. 10.2106/JBJS.19.00790
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures
J Bone Joint Surg Am. 2020 ;():. 10.2106/JBJS.19.00790
Metabolic Disorders
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543
This study has been identified as potentially high impact.
OE's AI-driven High Impact metric estimates the influence a paper is likely to have by integrating signals from both the journal in which it is published and the scientific content of the article itself.
Developed using state-of-the-art natural language processing, the OE High Impact model more accurately predicts a study's future citation performance than journal impact factor alone.
This enables earlier recognition of clinically meaningful research and helps readers focus on articles most likely to shape future practice.
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
N Engl J Med. 2016 Oct 20;375(16):1532-1543
Metabolic Disorders
Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy
Superior gains in bone mineral density and estimated strength at the hip for romosozumab compared with teriparatide in women with postmenopausal osteoporosis transitioning from bisphosphonate therapy